Our Team

Cancer Prevention Pharmaceuticals, Inc. was founded by Dr. Frank Meyskens and Dr. Gene Gerner, both of whom are highly respected cancer prevention researchers involved in some of the largest and well-known oncology research institutions including the National Cancer Institute (NCI) and the Southwest Oncology Group (SWOG). Collectively, CPP’s team has more than 100 years of drug development, regulatory and commercialization experience.

Board of Directors, Management, and Scientific Teams
Jeffrey Jacob
Chairman of the Board and CEO
Richard L. Love
Eugene W. Gerner, PhD
Director and CSO
Dan Donovan
Director and CBO
Jon S. Saxe
Additional Management and Scientific Teams
Alfred M. Cohen, MD, FACS, FASCRS
Christopher R. Richied
Kathryn Grenier MPA, HSA
V.P. of Clinical Operations
Marc L. Tokars
V.P. of Clinical and Regulatory Affairs
Elizabeth Bruckheimer, PhD
Vice President, Drug Development
Willene Brondum
Assoc. VP of Regulatory Affairs & Quality Assurance
Robert B. MacArthur, PharmD, MS
Senior Advisor, Product Development and Statistics
Stephen J. Rochelle, MS, RAC
Regulatory Affairs
Patrick Shannon, PhD
Project Management and CMC
Michelle Boytim, PhD
Program Manager, Clinical Research
Christine Brannen
Director of Operations